TG Therapeutics Inc (TGTX)

Debt-to-assets ratio

		Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019
Long-term debt	US$ in thousands	244,158	102,537	101,326	100,118	98,908	97,700	96,503	71,135	71,135	68,947	67,249	66,788	—	—	—	7,716	15,074	22,233	29,201	28,970
Total assets	US$ in thousands	586,014	401,207	373,323	329,587	331,067	220,854	197,358	193,572	217,891	251,666	303,028	379,629	409,687	481,400	548,699	625,642	273,856	294,621	101,849	163,014
Debt-to-assets ratio		0.42	0.26	0.27	0.30	0.30	0.44	0.49	0.37	0.33	0.27	0.22	0.18	0.00	0.00	0.00	0.01	0.06	0.08	0.29	0.18

September 30, 2024 calculation

Debt-to-assets ratio = Long-term debt ÷ Total assets
= $244,158K ÷ $586,014K
= 0.42

The debt-to-assets ratio of TG Therapeutics Inc has shown some fluctuations over the past few quarters. As of September 30, 2024, the ratio stands at 0.42, indicating that 42% of the company's assets are financed by debt.

Looking back over the past five quarters, the ratio has ranged from 0.18 to 0.49, with the highest ratio recorded in March 31, 2023, and the lowest in December 31, 2021. This suggests that the company has varied in its dependency on debt to finance its assets during this period.

Overall, the trend in the debt-to-assets ratio indicates that TG Therapeutics Inc has been managing its debt levels relative to its asset base, maintaining a moderate level of leverage. Monitoring this ratio in conjunction with other financial metrics can provide insights into the company's financial health and risk profile.